Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 39,947 |
|
|||||
| News | - | ||||||
| Day High | 1.08 | Low High |
|||||
| Day Low | 1.02 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Talphera Inc | TLPH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.07 | -6.25% | 1.05 | 00:00:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.08 | 1.02 | 1.08 | 1.05 | 1.12 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 241 | 39,947 | $ 1.04 | $ 41,693 | - | 0.72 - 1.61 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:45:45 | 49 | $ 1.02 | USD |
Talphera Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 17.82M | 16.97M | - | 651k | -18.4M | -1.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Talphera News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TLPH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.03 | 1.14 | 0.92 | 1.05 | 89,741 | 0.02 | 1.94% |
| 1 Month | 1.09 | 1.24 | 0.92 | 1.09 | 78,623 | -0.04 | -3.67% |
| 3 Months | 1.05 | 1.61 | 0.84 | 1.16 | 102,800 | 0.00 | 0.00% |
| 6 Months | 0.86 | 1.61 | 0.72 | 1.11 | 118,316 | 0.19 | 22.09% |
| 1 Year | 0.86 | 1.61 | 0.72 | 1.11 | 118,316 | 0.19 | 22.09% |
| 3 Years | 0.86 | 1.61 | 0.72 | 1.11 | 118,316 | 0.19 | 22.09% |
| 5 Years | 0.86 | 1.61 | 0.72 | 1.11 | 118,316 | 0.19 | 22.09% |
Talphera Description
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. |
